InvestSMART

Imugene Limited (ASX: IMU) - Announcements

Current share price for IMU : $0.071 0.002 (2.74%)+

ASX company news and announcements for Imugene Limited (IMU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Imugene Limited (IMU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Imugene Limited (IMU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Imugene Limited (IMU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$35 Imugene Oncolytic Virotherapy CF33 Patent Allowed in the US 19 Jul 2023 9:51AM $0.093 $0.071 fallen by 23.66%
$35 Imugene Appoints Dr Weitzman Interim Chief Medical Officer 18 Jul 2023 5:05PM $0.093 $0.071 fallen by 23.66%
$35 Roadshow investor webinar with Professor Yuman Fong 18 Jul 2023 3:44PM $0.094 $0.071 fallen by 24.47%
$35 Final Director's Interest Notice 7 Jul 2023 6:29PM $0.092 $0.071 fallen by 22.83%
$35 New Dose Escalation in Phase I Clinical Trial of CHECKvacc 7 Jul 2023 8:56AM $0.092 $0.071 fallen by 22.83%
$35 Letter to Shareholders 6 Jul 2023 8:25AM $0.094 $0.071 fallen by 24.47%
$35 Change of Director's Interest Notice 30 Jun 2023 4:33PM $0.091 $0.071 fallen by 21.98%
$35 HER-Vaxx induced antibodies correlated with tumour reduction 30 Jun 2023 8:40AM $0.089 $0.071 fallen by 20.22%
$35 Imugene PD1-Vaxx patent extended to 2040 29 Jun 2023 8:39AM $0.091 $0.071 fallen by 21.98%
$35 Initial Director's Interest Notice 23 Jun 2023 4:35PM $0.089 $0.071 fallen by 20.22%
$35 Imugene Appoints Kim Drapkin as Non-Executive Director 21 Jun 2023 8:25AM $0.097 $0.071 fallen by 26.80%
$35 Imugene Advances VAXINIA MAST Trial to Next IV Cohorts 9 Jun 2023 8:56AM $0.093 $0.071 fallen by 23.66%
$35 Imugene doses first combination patient in PD1-Vaxx trial 1 Jun 2023 9:02AM $0.110 $0.071 fallen by 35.45%
$35 Imugene Investor Webinar - FDA IND Clearance for onCARlytics 19 May 2023 12:24PM $0.123 $0.071 fallen by 42.04%
$35 FDA clears Imugene IND for onCARlytics first-in-class study 19 May 2023 8:35AM $0.115 $0.071 fallen by 38.26%
$35 onCARlytics with ARTEMIS T cells show anti-tumour activity 18 May 2023 9:04AM $0.115 $0.071 fallen by 38.26%
$35 onCARlytics with Artemis T cells abstract presented at ASGCT 3 May 2023 8:37AM $0.125 $0.071 fallen by 43.20%
$35 Quarterly Activities/Appendix 4C Cash Flow Report 28 Apr 2023 8:18AM $0.125 $0.071 fallen by 43.20%
$35 Imugene receives $12.6m R&D tax refund 26 Apr 2023 9:00AM $0.130 $0.071 fallen by 45.38%
$35 Imugene Images and Follows CHECKVacc in TNBC Patients 20 Apr 2023 8:33AM $0.140 $0.071 fallen by 49.29%
$35 First patients dosed in IT & IV cohort 3 of VAXINIA trial 5 Apr 2023 9:35AM $0.130 $0.071 fallen by 45.38%
$35 Imugene Presentation to NWR Healthcare Conference 22 Mar 2023 9:47AM $0.130 $0.071 fallen by 45.38%
$35 Imugene to present at NWR Virtual Healthcare Conference 16 Mar 2023 10:01AM $0.120 $0.071 fallen by 40.83%
$35 Imugene Corporate Presentation 15 Mar 2023 11:55AM $0.120 $0.071 fallen by 40.83%
$35 Notice Under Section 708A 10 Mar 2023 5:15PM $0.125 $0.071 fallen by 43.20%

326 - 350 of 1191 results

Page 14 of 48

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.